408 related articles for article (PubMed ID: 18559621)
1. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
4. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
5. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
6. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
7. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
9. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.
Frenzel LP; Patz M; Pallasch CP; Brinker R; Claasen J; Schulz A; Hallek M; Kashkar H; Wendtner CM
Br J Haematol; 2011 Jan; 152(2):191-200. PubMed ID: 21091905
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
11. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
12. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
[TBL] [Abstract][Full Text] [Related]
13. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
14. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
17. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
[TBL] [Abstract][Full Text] [Related]
18. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.
Thornton PD; Matutes E; Bosanquet AG; Lakhani AK; Grech H; Ropner JE; Joshi R; Mackie PH; Douglas ID; Bowcock SJ; Catovsky D
Ann Hematol; 2003 Dec; 82(12):759-65. PubMed ID: 14551737
[TBL] [Abstract][Full Text] [Related]
19. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
Zhong Y; Bakke AC; Fan G; Braziel RM; Gatter KM; Leis JF; Maziarz RT; Huang JZ
Cytometry B Clin Cytom; 2007 May; 72(3):189-95. PubMed ID: 17226861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
